{"filing":{"accession_number":"0001477932-26-004165","cik":"0001187953","ticker":"CELZ","company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"celz_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1187953/000147793226004165/celz_8k.htm"},"events":[{"id":15848,"run_id":14139,"accession_number":"0001477932-26-004165","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The Company entered into warrant exercise inducement agreements resulting in the issuance of new unregistered warrants to purchase 5,580,680 shares of common stock in a private placement, generating $4.5 million in gross proceeds and creating substantial future dilution to existing shareholders.","company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13754,"accession_number":"0001477932-26-004165","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Company entered into warrant exercise inducement agreements resulting in the issuance of new warrants to purchase 5,580,680 shares of common stock in a private placement under Section 4(a)(2) of the Securities Act. This is a dilutive equity issuance that raises capital ($4.5 million gross proceeds) and creates substantial future dilution through the Inducement Warrants, which are unregistered securities requiring stockholder approval and a resale registration statement. The transaction structure—exchanging cash exercise of existing warrants for new warrants at a reduced exercise price—is characteristic of a dilutive capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:18:04.872324+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13755,"accession_number":"0001477932-26-004165","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 explicitly addresses unregistered sales of equity securities. The filing references Item 1.01 (which typically covers material agreements or transactions), indicating a dilutive equity issuance. Unregistered equity sales are material events that affect shareholder ownership and capital structure, particularly for smaller-cap issuers like CELZ.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:18:04.872324+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":15849,"run_id":14139,"accession_number":"0001477932-26-004165","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Compensation Committee approved a $100,000 bonus payment to Timothy Warbington, the Chief Executive Officer.","company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13756,"accession_number":"0001477932-26-004165","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Compensation Committee approved a $100,000 bonus payment to Timothy Warbington, the CEO. This is a direct disclosure of a compensatory arrangement for a named executive officer under Item 5.02(e), distinct from an appointment or departure. The bonus approval is material to investors assessing executive compensation practices and cash outflows.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:18:04.872324+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13754,"accession_number":"0001477932-26-004165","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Company entered into warrant exercise inducement agreements resulting in the issuance of new warrants to purchase 5,580,680 shares of common stock in a private placement under Section 4(a)(2) of the Securities Act. This is a dilutive equity issuance that raises capital ($4.5 million gross proceeds) and creates substantial future dilution through the Inducement Warrants, which are unregistered securities requiring stockholder approval and a resale registration statement. The transaction structure—exchanging cash exercise of existing warrants for new warrants at a reduced exercise price—is characteristic of a dilutive capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:18:04.872324+00:00","company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","filing_date":"2026-07-02"},{"id":13755,"accession_number":"0001477932-26-004165","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 explicitly addresses unregistered sales of equity securities. The filing references Item 1.01 (which typically covers material agreements or transactions), indicating a dilutive equity issuance. Unregistered equity sales are material events that affect shareholder ownership and capital structure, particularly for smaller-cap issuers like CELZ.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:18:04.872324+00:00","company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","filing_date":"2026-07-02"},{"id":13756,"accession_number":"0001477932-26-004165","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Compensation Committee approved a $100,000 bonus payment to Timothy Warbington, the CEO. This is a direct disclosure of a compensatory arrangement for a named executive officer under Item 5.02(e), distinct from an appointment or departure. The bonus approval is material to investors assessing executive compensation practices and cash outflows.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:18:04.872324+00:00","company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","filing_date":"2026-07-02"}]}